Technetium-99m-alendronate: a new radiopharmaceutical for bone scanning

Area of Science:

• Nuclear medicine
• Radiopharmaceutical chemistry
• Biomedical imaging

Background:

• Bone scanning relies on radiopharmaceuticals to visualize bone metabolism.
• Current agents like 99mTc-etidronate (HEDP) and 99mTc-medronate (MDP) have limitations.
• Alendronate (ABP), a bisphosphonate used for osteoporosis, offers a potential chelating agent for technetium-99m (99mTc) due to its amino group.

Purpose of the Study:

• To prepare and evaluate a novel 99mTc-radiopharmaceutical utilizing alendronate (ABP) as the chelating agent.
• To assess the stability and labeling efficiency of the new 99mTc-ABP complex.
• To determine the preliminary suitability of 99mTc-ABP for bone scanning applications.

Main Methods:

• A sterile dry kit was formulated containing alendronate (ABP), a reducing agent (stannous fluoride), and a stabilizer (gentisic acid).
• Optimal formulation parameters including molar concentrations, pH, and shelf life were investigated.
• Labeling efficiency and radiochemical purity were assessed using varying amounts of 99mTc pertechnetate (99mTcO4-) at room temperature.
• Initial in vivo testing was conducted in rabbits.

Main Results:

• The prepared kit yielded a labeling efficiency exceeding 95% for 99mTc-ABP.
• The radiopharmaceutical demonstrated stability for up to 5 hours.
• Preliminary studies in rabbits indicated that 99mTc-ABP is a promising agent for bone scanning.

Conclusions:

• A stable and highly efficient 99mTc-radiopharmaceutical based on alendronate (ABP) has been successfully prepared.
• The novel 99mTc-ABP complex shows potential as an improved agent for bone scintigraphy.
• Further studies are warranted to evaluate biodistribution and radiopharmacokinetic parameters in animals and humans.